Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross‐over study
- 27 May 2004
- journal article
- clinical trial
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 19 (5) , 343-346
Abstract
Increasing evidence suggests that the cholinergic system is involved in the pathogenesis of schizophrenia. Donepezil, a central cholinesterase inhibitor, improves psychotic symptomatology in demented patients, however, evidence for its role in the management of active psychosis in schizophrenia remains limited. An 18‐week double blind cross‐over study was conducted in which eight patients were randomly assigned to either donepezil (5 mg/day for the first 4 weeks and 10 mg/day for the following 4 weeks) or placebo as augmentation treatment to clozapine. After this initial phase, there was a 2‐week washout period of the study medication after which the same regimen was crossed over at the same dose and for the same period (8 weeks). No significant difference was noted in the total positive and negative symptom scale scores when donepezil was compared with placebo (16.7%+12.97% vs 3.20%+13.94% respectively, p = 0.18). However, three patients improved (>15%) in the total PANSS scores (37.03%, 16.6% and 25.33%) during the donepezil treatment phase, while only one patient improved (20.87%) during the placebo phase. No differences were noted in the Calgary depression scale (p = 0.305), Simpson Angus scale (p = 0.374), clinical global impression‐improvement scale (p = 0.23) and clinical global impression‐severity of illness scores (p = 0.116). Although this preliminary study failed to demonstrate a clear effect of donepezil augmentation in clozapine treated chronic schizophrenia patients, it seems that the subtle positive effect of donepezil observed in some of our patients should encourage further investigation in a larger sample of this patient subpopulation. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 34 references indexed in Scilit:
- In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in SchizophreniaAmerican Journal of Psychiatry, 2003
- Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophreniaMolecular Psychiatry, 2002
- Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled studyJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Cholinergic systems and schizophrenia: primary pathology or epiphenomena?Journal of Chemical Neuroanatomy, 2001
- A Double-blind Placebo-controlled Case Study of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient: Functional MRI Correlates.Neurocase, 2001
- Sulpiride augmentation in people with schizophrenia partially responsive to clozapineThe British Journal of Psychiatry, 1997
- Nicotinic Receptor Function in SchizophreniaSchizophrenia Bulletin, 1996
- Muscarinic cholinergic hyperactivity in schizophreniaSchizophrenia Research, 1991
- The current status of the dopamine hypothesis of schizophreniaNeuropsychopharmacology, 1988
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970